Opportunity Information: Apply for PA 13 165
Apply for PA 13 165
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.361 Nursing Research 93.393 Cancer Cause and Prevention Research 93.399 Cancer Control.
- This funding opportunity was created on Mar 29, 2013 and posted on Mar 29, 2013.
- Applicants must submit their applications by May 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- Eligible applicants include: Small businesses Public and State controlled institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) County governments City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Special district governments Private institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) grant opportunity "Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R01)" (Funding Opportunity Number PA-13-165) was created to push symptom management research beyond the limits of traditional randomized controlled trials (RCTs). The main idea is that classic RCT designs, while valuable, often do not reflect how chronic illness symptoms are actually treated in real life, where clinicians adjust strategies over time based on how a person is responding. This program encourages researchers to use newer, more flexible clinical trial designs that can better capture individual differences in treatment response, improve participant retention, and address common challenges like adherence to symptom management regimens. The ultimate goal is to produce evidence that more directly translates into practical, effective approaches for preventing or reducing symptom burden in people living with chronic illness.
A central example highlighted in the announcement is the Sequential Multiple Assignment Randomized Trial (SMART) design. SMART studies are built around the reality that a single fixed intervention does not work the same way for everyone, and that people often need changes in intensity or type of support as treatment progresses. In a SMART framework, participants can be randomized more than once at different decision points during the study. Those decision points are triggered by pre-specified rules, such as whether a participant is improving, not improving, or experiencing side effects or barriers. Based on those rules, the study can reassign participants to different intervention components, higher or lower "doses" of an intervention, or alternative strategies. This creates a structured way to develop and test adaptive or dynamic treatment regimens that are tailored to individual needs and trajectories, rather than assuming one standardized plan is optimal for all patients throughout the entire trial.
The opportunity specifically targets symptom management in chronic illness, emphasizing that symptom burden often changes over time and varies widely from person to person. By using innovative and pragmatic research designs, applicants are expected to identify which sequences or combinations of treatment components work best, for whom, and under what circumstances. The NIH frames this as a way to better address heterogeneous treatment effects (different responses across patients), reduce dropout and improve retention, and incorporate adherence realities into the trial design rather than treating them as after-the-fact complications. The emphasis on pragmatic approaches also signals interest in designs that mimic clinical care, where ongoing reassessment and adjustment are routine.
Administratively, this is a discretionary grant mechanism using the NIH R01 funding instrument. The funding announcement listed an award ceiling of $350,000. No cost sharing or matching was required. The opportunity was posted and created on March 29, 2013, with an original and final closing date of May 7, 2016, and it was archived on June 7, 2016. The program was associated with CFDA numbers 93.361 (Nursing Research), 93.393 (Cancer Cause and Prevention Research), and 93.399 (Cancer Control), which signals that relevant projects could sit within nursing science and symptom-focused research broadly, including symptom issues in cancer prevention, control, and survivorship contexts, as well as other chronic illnesses.
Eligibility was broad and included many types of domestic organizations: small businesses; public and private institutions of higher education; nonprofit organizations (both 501(c)(3) and non-501(c)(3) categories); for-profit organizations (including those other than small businesses); and a variety of government entities (state, county, city/township, special district governments, and independent school districts). It also included Native American tribal governments (both federally recognized and other than federally recognized) and tribal organizations. The announcement explicitly noted additional eligible applicant types such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations, regional organizations, eligible federal agencies, and U.S. territories or possessions. At the same time, foreign institutions were not eligible to apply, non-U.S. components of U.S. organizations were not eligible, and foreign components as defined by NIH policy were not allowed, making this a strictly domestic opportunity in terms of applicant and project components.
For more details, the full announcement was hosted by NIH at http://grants.nih.gov/grants/guide/pa-files/PA-13-165.html, and the NIH Office of Extramural Research (OER) webmaster contact was provided for access or linking issues.
Frequently Asked Questions (FAQs)
What is the official name of this NIH funding opportunity?
The opportunity is titled "Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R01)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PA-13-165.
What is the main purpose of this grant opportunity?
The purpose is to advance symptom management research in chronic illness by encouraging study designs that go beyond traditional randomized controlled trials (RCTs), with an emphasis on approaches that better reflect real-world clinical care where treatment strategies are adjusted over time based on patient response.
Why does the announcement emphasize moving beyond classic randomized controlled trials (RCTs)?
The announcement notes that traditional RCT designs, while valuable, may not reflect how symptoms in chronic illness are treated in real life. In practice, clinicians often adjust interventions over time based on whether a person is improving, experiencing side effects, or facing barriers to adherence. The opportunity encourages methods that can capture these realities.
What types of research designs does NIH encourage under this program?
NIH encourages newer, more flexible and pragmatic clinical trial designs that can better capture individual differences in treatment response, improve participant retention, and address common challenges such as adherence to symptom management regimens.
What is the ultimate goal of the research supported by this opportunity?
The ultimate goal is to generate evidence that more directly translates into practical, effective approaches for preventing or reducing symptom burden in people living with chronic illness.
What is a SMART design, and why is it highlighted?
SMART stands for Sequential Multiple Assignment Randomized Trial. It is highlighted as a central example because it is designed around the reality that a single fixed intervention may not work equally well for everyone, and that people may need changes in the type or intensity of support as treatment progresses.
How does a SMART trial work in general terms?
In a SMART framework, participants may be randomized more than once at different decision points during the study. Those decision points occur according to pre-specified rules, such as whether a participant is improving, not improving, or encountering side effects or barriers. Based on these rules, participants can be reassigned to different intervention components, different "doses" or intensity levels, or alternative strategies.
What is meant by "adaptive" or "dynamic" treatment regimens in this announcement?
The announcement uses SMART as an example of a structured way to develop and test treatment regimens that are adjusted over time and tailored to individual needs and trajectories, rather than assuming one standardized plan is best for all participants throughout the entire trial.
What kind of health focus does this opportunity target?
The opportunity specifically targets symptom management in chronic illness, emphasizing that symptom burden can change over time and vary widely between individuals.
What kinds of questions are applicants expected to address?
Applicants are expected to use innovative and pragmatic designs to identify which sequences or combinations of intervention components work best, for whom, and under what circumstances.
What does the announcement mean by "heterogeneous treatment effects"?
It refers to the idea that different patients can respond differently to the same symptom management approach, and the opportunity encourages designs that can better detect and make use of these differences.
How does this opportunity address participant retention and dropout?
The announcement explicitly notes an interest in designs that can reduce dropout and improve retention, including by aligning study procedures more closely with real-world care and by incorporating response-based adjustments over time.
How does the opportunity treat adherence issues?
It encourages designs that incorporate adherence realities into the trial design, rather than treating adherence problems as complications to deal with only after the study is underway or completed.
What is the NIH grant mechanism used for this program?
This is a discretionary grant opportunity using the NIH R01 funding instrument.
What is the award ceiling listed in the announcement?
The announcement listed an award ceiling of $350,000.
Is cost sharing or matching required?
No. The announcement states that no cost sharing or matching was required.
When was this funding opportunity posted and created?
It was posted and created on March 29, 2013.
What were the closing dates for this opportunity?
The original closing date and the final closing date were both May 7, 2016.
Is this opportunity still active?
No. The announcement was archived on June 7, 2016.
Which CFDA numbers are associated with this program?
The program was associated with CFDA numbers 93.361 (Nursing Research), 93.393 (Cancer Cause and Prevention Research), and 93.399 (Cancer Control).
What do the listed CFDA numbers suggest about the research areas?
They suggest that relevant projects may align with nursing science and symptom-focused research broadly, including symptom issues in cancer prevention, cancer control, and survivorship contexts, as well as other chronic illnesses.
Who is eligible to apply?
Eligibility is broad for domestic organizations and includes: small businesses; public and private institutions of higher education; nonprofit organizations (both 501(c)(3) and non-501(c)(3)); for-profit organizations (including those other than small businesses); and government entities such as state, county, city/township, special district governments, and independent school districts.
Are tribal governments and tribal organizations eligible?
Yes. The announcement includes Native American tribal governments (both federally recognized and other than federally recognized) and tribal organizations as eligible applicants.
Are minority-serving institutions specifically mentioned as eligible?
Yes. The announcement explicitly notes eligibility for Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Are faith-based or community-based organizations eligible?
Yes. The announcement explicitly includes faith-based or community-based organizations.
Are U.S. territories or possessions eligible?
Yes. The announcement includes U.S. territories or possessions among eligible applicants.
Are foreign institutions allowed to apply?
No. Foreign institutions were not eligible to apply.
Can a U.S. organization include a non-U.S. component in the project?
No. The announcement states that non-U.S. components of U.S. organizations were not eligible.
Are foreign components allowed under NIH policy for this opportunity?
No. The announcement states that foreign components (as defined by NIH policy) were not allowed.
Where can applicants find the full funding announcement?
The full announcement was hosted by NIH at: http://grants.nih.gov/grants/guide/pa-files/PA-13-165.html
Who is listed as the contact for access or linking issues?
The NIH Office of Extramural Research (OER) webmaster contact was provided for access or linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R15)
Previous opportunity: Conformance with the Manufactured Food Regulatory Program Standards (MFRPS) (U18)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 165
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 165) also looked into and applied for these:
| Funding Opportunity |
|---|
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R15) Apply for PA 13 166 Funding Number: PA 13 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R21) Apply for PA 13 167 Funding Number: PA 13 167 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01) Apply for PAR 13 159 Funding Number: PAR 13 159 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Academic Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) Apply for PAR 13 169 Funding Number: PAR 13 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Dissertation Research (R36) Apply for PAR 13 182 Funding Number: PAR 13 182 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research in Integrative Cancer Biology (U01) Apply for PAR 13 184 Funding Number: PAR 13 184 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Image guided Drug Delivery in Cancer (R01) Apply for PAR 13 185 Funding Number: PAR 13 185 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R01) Apply for RFA MH 14 170 Funding Number: RFA MH 14 170 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R21) Apply for RFA MH 14 171 Funding Number: RFA MH 14 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Detection of Pathogen Induced Cancer (DPIC) (R01) Apply for PAR 13 190 Funding Number: PAR 13 190 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 13 176 Funding Number: PAR 13 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Imaging and Biomarkers for Early Cancer Detection (R01) Apply for PAR 13 189 Funding Number: PAR 13 189 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications to R01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (R01) Apply for PAR 13 177 Funding Number: PAR 13 177 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50) Apply for PAR 13 174 Funding Number: PAR 13 174 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to R01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (R01) Apply for PAR 13 172 Funding Number: PAR 13 172 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to U01 Awards on Detection of Pathogen Induced Cancer (DPIC) (U01) Apply for PAR 13 173 Funding Number: PAR 13 173 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P01) Apply for PAR 13 175 Funding Number: PAR 13 175 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P50 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P50) Apply for PAR 13 170 Funding Number: PAR 13 170 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revisions to P01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (P01) Apply for PAR 13 171 Funding Number: PAR 13 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Paul Calabresi Career Development Award for Clinical Oncology (K12) Apply for PAR 13 201 Funding Number: PAR 13 201 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 165", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.